MGNX Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of 23.1% compared to MacroGenics, Inc.'s net margin of 39.21%. MacroGenics, Inc.'s return on equity of -88.47% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

MacroGenics, Inc. has a consensus price target of $3.40, signalling upside risk potential of 111.18%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 6.16%. Given that MacroGenics, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe MacroGenics, Inc. is more attractive than Gilead Sciences, Inc..

MacroGenics, Inc. has a beta of 1.516, which suggesting that the stock is 51.583% more volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.

MacroGenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.53% to investors and pays a quarterly dividend of $0.79 per share. MacroGenics, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

MacroGenics, Inc. quarterly revenues are $72.8M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. MacroGenics, Inc.'s net income of $16.8M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, MacroGenics, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 19.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MacroGenics, Inc. is 0.79x versus 5.39x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 23.1% compared to MacroGenics, Inc.'s net margin of 33.68%. MacroGenics, Inc.'s return on equity of -88.47% beat Merck & Co., Inc.'s return on equity of 39.63%.

MacroGenics, Inc. has a consensus price target of $3.40, signalling upside risk potential of 111.18%. On the other hand Merck & Co., Inc. has an analysts' consensus of $110.04 which suggests that it could grow by 3.05%. Given that MacroGenics, Inc. has higher upside potential than Merck & Co., Inc., analysts believe MacroGenics, Inc. is more attractive than Merck & Co., Inc..

MacroGenics, Inc. has a beta of 1.516, which suggesting that the stock is 51.583% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.604%.

MacroGenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.07% to investors and pays a quarterly dividend of $0.85 per share. MacroGenics, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

MacroGenics, Inc. quarterly revenues are $72.8M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. MacroGenics, Inc.'s net income of $16.8M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, MacroGenics, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 14.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MacroGenics, Inc. is 0.79x versus 4.21x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 23.1% compared to MacroGenics, Inc.'s net margin of 21.32%. MacroGenics, Inc.'s return on equity of -88.47% beat Pfizer Inc.'s return on equity of 10.84%.

MacroGenics, Inc. has a consensus price target of $3.40, signalling upside risk potential of 111.18%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.08%. Given that MacroGenics, Inc. has higher upside potential than Pfizer Inc., analysts believe MacroGenics, Inc. is more attractive than Pfizer Inc..

MacroGenics, Inc. has a beta of 1.516, which suggesting that the stock is 51.583% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

MacroGenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.86% to investors and pays a quarterly dividend of $0.43 per share. MacroGenics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

MacroGenics, Inc. quarterly revenues are $72.8M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. MacroGenics, Inc.'s net income of $16.8M is lower than Pfizer Inc.'s net income of $3.6B. Notably, MacroGenics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MacroGenics, Inc. is 0.79x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 23.1% compared to MacroGenics, Inc.'s net margin of 38.89%. MacroGenics, Inc.'s return on equity of -88.47% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

MacroGenics, Inc. has a consensus price target of $3.40, signalling upside risk potential of 111.18%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $795.38 which suggests that it could grow by 1.33%. Given that MacroGenics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe MacroGenics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

MacroGenics, Inc. has a beta of 1.516, which suggesting that the stock is 51.583% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

MacroGenics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. MacroGenics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

MacroGenics, Inc. quarterly revenues are $72.8M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. MacroGenics, Inc.'s net income of $16.8M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, MacroGenics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MacroGenics, Inc. is 0.79x versus 6.07x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.